Dudnik et al. reported that BRAF-mutated NSCLC tends to present high PD-L1 expression without high TMB or MSI-high, and PFS was 3.7 months and 4.1 months in BRAFV600E-mutated and non-BRAFV600E-mutated patients with ICI treatment, respectively [133]. Here, BRAF is linked to non-small cell lung carcinoma.